Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 5
1948 2
1949 3
1950 7
1951 4
1952 14
1953 10
1954 13
1955 14
1956 10
1957 6
1958 18
1959 3
1962 1
1963 44
1964 35
1965 18
1966 18
1967 8
1968 16
1969 8
1970 6
1971 5
1972 1
1973 9
1974 5
1975 2
1976 4
1977 10
1978 5
1979 3
1980 1
1981 9
1982 10
1983 4
1984 8
1985 3
1986 4
1987 1
1988 6
1989 11
1990 5
1991 6
1992 3
1993 10
1994 13
1995 18
1996 20
1997 21
1998 9
1999 13
2000 9
2001 15
2002 16
2003 29
2004 37
2005 32
2006 25
2007 29
2008 45
2009 50
2010 45
2011 52
2012 77
2013 95
2014 95
2015 96
2016 90
2017 88
2018 94
2019 103
2020 160
2021 223
2022 290
2023 328
2024 125

Text availability

Article attribute

Article type

Publication date

Search Results

2,496 results

Results by year

Filters applied: . Clear all
The following term was ignored: %
The following term was not found in PubMed: 20Moaven
Page 1
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision.
Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, Brignardello-Petersen R, Canonica GW, Casale T, Chavannes NH, Correia de Sousa J, Cruz AA, Cuello-Garcia CA, Demoly P, Dykewicz M, Etxeandia-Ikobaltzeta I, Florez ID, Fokkens W, Fonseca J, Hellings PW, Klimek L, Kowalski S, Kuna P, Laisaar KT, Larenas-Linnemann DE, Lødrup Carlsen KC, Manning PJ, Meltzer E, Mullol J, Muraro A, O'Hehir R, Ohta K, Panzner P, Papadopoulos N, Park HS, Passalacqua G, Pawankar R, Price D, Riva JJ, Roldán Y, Ryan D, Sadeghirad B, Samolinski B, Schmid-Grendelmeier P, Sheikh A, Togias A, Valero A, Valiulis A, Valovirta E, Ventresca M, Wallace D, Waserman S, Wickman M, Wiercioch W, Yepes-Nuñez JJ, Zhang L, Zhang Y, Zidarn M, Zuberbier T, Schünemann HJ. Brożek JL, et al. J Allergy Clin Immunol. 2017 Oct;140(4):950-958. doi: 10.1016/j.jaci.2017.03.050. Epub 2017 Jun 8. J Allergy Clin Immunol. 2017. PMID: 28602936 Free article.
New evidence has accumulated since the last revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines in 2010, prompting its update. OBJECTIVE: We sought to provide a targeted update of the ARIA guidelines. METHODS: The ARIA guideline panel …
New evidence has accumulated since the last revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines in 2010, pro …
Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.
Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Hampel H, et al. Brain. 2023 Nov 2;146(11):4414-4424. doi: 10.1093/brain/awad188. Brain. 2023. PMID: 37280110 Free PMC article. Review.
This review provides a comprehensive state-of-the-art conceptual review of radiological features, clinical detection and classification challenges, pathophysiology, underlying biological mechanism(s) and risk factors/predictors associated with ARIA. We summarize the existi …
This review provides a comprehensive state-of-the-art conceptual review of radiological features, clinical detection and classification chal …
Lecanemab: Appropriate Use Recommendations.
Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, Hendrix S, Selkoe D, Weiner M, Petersen RC, Salloway S. Cummings J, et al. J Prev Alzheimers Dis. 2023;10(3):362-377. doi: 10.14283/jpad.2023.30. J Prev Alzheimers Dis. 2023. PMID: 37357276 Free PMC article.
Adverse events may occur with lecanemab including amyloid related imaging abnormalities (ARIA) and infusion reactions. Monitoring guidelines for these events are detailed in this AUR. Most ARIA with lecanemab is asymptomatic, but a few cases are serious or, very rar …
Adverse events may occur with lecanemab including amyloid related imaging abnormalities (ARIA) and infusion reactions. Monitoring gui …
Amyloid-Related Imaging Abnormalities: An Update.
Roytman M, Mashriqi F, Al-Tawil K, Schulz PE, Zaharchuk G, Benzinger TLS, Franceschi AM. Roytman M, et al. AJR Am J Roentgenol. 2023 Apr;220(4):562-574. doi: 10.2214/AJR.22.28461. Epub 2022 Nov 2. AJR Am J Roentgenol. 2023. PMID: 36321981 Review.
The entity can be broadly categorized into ARIA characterized by edema and effusion (ARIA-E) and ARIA characterized by microhemorrhages and superficial siderosis (ARIA-H). ...ARIA is often asymptomatic and self-resolving. The recognition of A …
The entity can be broadly categorized into ARIA characterized by edema and effusion (ARIA-E) and ARIA characterized by …
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, Suhy J, Forrestal F, Tian Y, Umans K, Wang G, Singhal P, Budd Haeberlein S, Smirnakis K. Salloway S, et al. JAMA Neurol. 2022 Jan 1;79(1):13-21. doi: 10.1001/jamaneurol.2021.4161. JAMA Neurol. 2022. PMID: 34807243 Free PMC article. Clinical Trial.
Common associated symptoms among 103 patients with symptomatic ARIA-E or ARIA-H were headache (48 [46.6%]), confusion (15 [14.6%]), dizziness (11 [10.7%]), and nausea (8 [7.8%]). ...ARIA-microhemorrhage and ARIA-superficial siderosis occurred in 197 pa …
Common associated symptoms among 103 patients with symptomatic ARIA-E or ARIA-H were headache (48 [46.6%]), confusion (15 [14. …
ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease.
Honig LS, Barakos J, Dhadda S, Kanekiyo M, Reyderman L, Irizarry M, Kramer LD, Swanson CJ, Sabbagh M. Honig LS, et al. Alzheimers Dement (N Y). 2023 Mar 20;9(1):e12377. doi: 10.1002/trc2.12377. eCollection 2023 Jan-Mar. Alzheimers Dement (N Y). 2023. PMID: 36949897 Free PMC article.
RESULTS: In the phase 2 core and OLE, there was a low incidence of ARIA-E (<10%), with <3% symptomatic cases. ARIA-E was generally asymptomatic, mild-to-moderate in severity, and occurred early (<3 months). ...ARIA-H and ARIA-E occurred with s …
RESULTS: In the phase 2 core and OLE, there was a low incidence of ARIA-E (<10%), with <3% symptomatic cases. ARIA-E was …
Aducanumab: Appropriate Use Recommendations Update.
Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova LG, Hendrix S, Sabbagh M, Selkoe D, Weiner M, Salloway S. Cummings J, et al. J Prev Alzheimers Dis. 2022;9(2):221-230. doi: 10.14283/jpad.2022.34. J Prev Alzheimers Dis. 2022. PMID: 35542993 Free PMC article.
The apolipoprotein E epsilon4 (APOE4) genotype is strongly associated with ARIA and exhibits a gene dose effect. We recommend that clinicians perform APOE genotyping to better inform patient care decisions, discussions regarding risk, and clinician vigilance concerning …
The apolipoprotein E epsilon4 (APOE4) genotype is strongly associated with ARIA and exhibits a gene dose effect. We recommend that cl …
Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.
Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F. Filippi M, et al. JAMA Neurol. 2022 Mar 1;79(3):291-304. doi: 10.1001/jamaneurol.2021.5205. JAMA Neurol. 2022. PMID: 35099507 Review.
Both ARIA types manifested early during study course, and symptomatic cases accounted for the 6.1% to 39.3% of ARIA-E cases at higher treatment doses across RCTs, whereas ARIA-H cases were generally asymptomatic. ...ARIA-E recurrence after dose reiniti …
Both ARIA types manifested early during study course, and symptomatic cases accounted for the 6.1% to 39.3% of ARIA-E cases at …
Aducanumab: Appropriate Use Recommendations.
Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Cummings J, et al. J Prev Alzheimers Dis. 2021;8(4):398-410. doi: 10.14283/jpad.2021.41. J Prev Alzheimers Dis. 2021. PMID: 34585212 Free PMC article.
Aducanumab can substantially increase the incidence of amyloid-related imaging abnormalities (ARIA) with brain effusion or hemorrhage. Dose interruption or treatment discontinuation is recommended for symptomatic ARIA and for moderate-severe ARIA. The Expert …
Aducanumab can substantially increase the incidence of amyloid-related imaging abnormalities (ARIA) with brain effusion or hemorrhage …
Association of Microglial Activation With Spontaneous ARIA-E and CSF Levels of Anti-Abeta Autoantibodies.
Piazza F, Caminiti SP, Zedde M, Presotto L, DiFrancesco JC, Pascarella R, Giossi A, Sessa M, Poli L, Basso G, Perani D. Piazza F, et al. Neurology. 2022 Sep 20;99(12):e1265-e1277. doi: 10.1212/WNL.0000000000200892. Epub 2022 Aug 8. Neurology. 2022. PMID: 35940900 Free PMC article.
However, the in vivo evidence for a direct association between neuroinflammation and ARIA-E in patients with high CSF anti-Abeta (auto)antibody levels has never been demonstrated. ...CSF anti-Abeta autoantibodies at presentation were high in all patients and markedly decre …
However, the in vivo evidence for a direct association between neuroinflammation and ARIA-E in patients with high CSF anti-Abeta (aut …
2,496 results